Discuss Anesthetic management of pheochromocytoma
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have comprehensive, high-quality content from Miller's Anesthesia, Campbell Walsh Wein Urology, and Sabiston's Surgery. I have enough to write a thorough, well-organized answer.
Anesthetic Management of Pheochromocytoma
Pheochromocytoma is a catecholamine-secreting tumor of chromaffin tissue. Anesthetic management is one of the most demanding in endocrine surgery, requiring meticulous preoperative preparation, vigilant intraoperative hemodynamic control, and careful postoperative monitoring.
1. Preoperative Preparation
Goals
The primary goals are to control hypertension, restore intravascular volume, and optimize end-organ function before surgery. The traditional Roizen criteria for adequacy of preoperative preparation are:
- Blood pressure < 165/90 mmHg for at least 24 hours preoperatively
- Orthostatic hypotension present (systolic > 80/45 mmHg)
- No ST-T wave changes on ECG for 1 week
- Fewer than 1 premature ventricular contraction in 5 minutes
The 2014 Endocrine Society guidelines recommend tighter targets: BP < 130/80 mmHg sitting (>90 mmHg standing), HR 60–70 bpm sitting (70–80 bpm standing).
Preoperative Cardiac Evaluation
Patients are at risk for catecholamine-induced cardiomyopathy. Preoperative ECG, echocardiography, and anesthesia/cardiology consultation are recommended, particularly in patients with symptoms of ventricular dysfunction.
α-Adrenergic Blockade
All patients with biochemically confirmed pheochromocytoma should receive preoperative catecholamine blockade, even in the absence of hypertension. Before routine preoperative α-blockade, mortality rates were as high as 50%; they now are < 3%.
| Agent | Type | Starting Dose | Notes |
|---|---|---|---|
| Phenoxybenzamine | Non-selective, non-competitive (irreversible) | 10 mg BD, titrate to 40 mg TDS | Gold standard; irreversible blockade persists postoperatively, causing hypotension |
| Doxazosin / Prazosin / Terazosin | Selective α₁, competitive | Doxazosin 2–8 mg/day | Fewer side effects; competitive — catecholamine surges can overcome blockade |
| Calcium channel blockers | Adjunct or alternative | Nicardipine, nifedipine | Used when α-blockers give inadequate control |
Preoperative α-blockade should last 7–14 days (>30 days is associated with more intraoperative bradycardia and postoperative hypotension). Non-selective alpha blockade may provide superior intraoperative hemodynamic stability compared to selective agents.
β-Adrenergic Blockade
β-blockers are added only after adequate α-blockade for patients with persistent tachycardia (epinephrine-secreting tumors). β-blockers must never be given first — unopposed α-adrenergic activity from removing β-mediated vasodilation can precipitate a hypertensive crisis.
Volume Expansion
Chronic catecholamine excess causes vasoconstriction and relative hypovolemia. Aggressive α-blockade typically restores euvolemia gradually (by increasing venous capacitance and stimulating thirst). Preoperative IV fluid expansion may be needed in inadequately prepared patients.
2. Intraoperative Management
Monitoring
- Intra-arterial line — mandatory in all cases; placed preinduction to allow immediate BP control
- Large-bore IV access — minimum 2 peripheral IVs
- Central venous access — considered (not routine) when postoperative vasoactive infusions are anticipated
- Transesophageal echocardiography (TEE) / pulmonary artery catheter — reserved for patients with ventricular dysfunction
- Standard monitoring: ECG (5-lead preferred), SpO₂, ETCO₂, temperature, urine output (Foley catheter)
Premedication
Anxiolysis with benzodiazepines or dexmedetomidine is beneficial — anxiety and sympathetic stimulation can trigger catecholamine surges before induction.
Induction
- A slow, controlled induction with adequate depth before laryngoscopy is essential
- Propofol — safe; blunts sympathetic response to intubation
- Etomidate — safe hemodynamically (used in patients with cardiomyopathy, noting cortisol suppression)
- Ketamine — avoid: causes sympathetic stimulation and catecholamine release
- Fentanyl (or remifentanil) in high dose before laryngoscopy to blunt the intubation response
- Lidocaine IV (1.5 mg/kg) prior to laryngoscopy can attenuate the pressor response
Drugs to Avoid
| Drug | Reason |
|---|---|
| Ketamine | Sympathomimetic — triggers catecholamine surge |
| Halothane | Sensitizes myocardium to catecholamine-induced arrhythmias |
| Ephedrine, indirect sympathomimetics | Stimulate catecholamine release |
| Pancuronium | Vagolytic tachycardia + catecholamine release |
| High-dose atracurium, morphine | Histamine release → catecholamine surge |
| Metoclopramide | Dopamine antagonist — can precipitate hypertensive crisis |
| Desflurane | Transient sympathetic activation, tachycardia |
Maintenance of Anesthesia
All standard inhalational agents (sevoflurane, isoflurane) and most opioids (fentanyl, remifentanil) are acceptable. Epidural analgesia combined with general anesthesia improves postoperative pain control but does not reliably attenuate intraoperative hypertensive episodes and may worsen post-vein ligation hypotension.
Hemodynamic Management — Two Phases
Phase 1: Pre-Vein Ligation (Tumor Manipulation)
Hypertensive crises are common during:
- Induction and intubation (catecholamine release from nerve endings)
- Surgical manipulation and tumor compression (massive intravascular catecholamine discharge)
Agents of choice (short-acting, rapid onset):
- Clevidipine — ultra-short-acting calcium channel blocker; preferred
- Nicardipine — IV infusion; calcium channel blocker
- Sodium nitroprusside — reliable vasodilator; titrate via infusion
- Nitroglycerin — IV bolus or infusion
- Esmolol — for tachyarrhythmias and rate control
- Phentolamine — IV α-blocker; onset is slower so less favored acutely
- Magnesium sulfate — 2–4 g loading dose before induction, followed by 1–2 g/hr infusion; acts as a direct vasodilator, stabilizes membranes, and decreases catecholamine release directly from the tumor — widely used adjunct
Phase 2: Post-Vein Ligation (Tumor Removal)
After adrenal vein ligation, the catecholamine source is removed. This causes:
- Rapid fall in circulating catecholamines
- Peripheral vasodilation + increased venous capacitance
- Potentially profound hypotension
Management:
- Aggressive volume loading during the resection phase (anticipate need)
- Discontinue vasodilators promptly
- Phenylephrine — first-line vasopressor (pure α-agonist)
- Norepinephrine — for patients whose tumor secreted predominantly norepinephrine
- Vasopressin or methylene blue — for refractory catecholamine-resistant hypotension
- Patients on irreversible phenoxybenzamine may need vasopressor support even with adequate volume repletion
Glucose Management
Excess catecholamines → insulin resistance + impaired secretion → intraoperative hyperglycemia. Correct judiciously, as glucose normalizes (or hypoglycemia supervenes) post-resection, especially in epinephrine-secreting tumors.
3. Postoperative Management
- Monitor in ICU for the first 24–48 hours (select hemodynamically stable, minimally invasive patients may go to a high-dependency unit)
- Continue invasive arterial pressure monitoring
- Vasopressor infusions may be required; choice guided by preoperative catecholamine profile
- Glucose monitoring every 1–2 hours for 6–24 hours — rebound hyperinsulinemia causes hypoglycemia, especially after epinephrine-secreting tumors and prolonged resections
- Approximately 50% of patients remain hypertensive for 1–3 days postoperatively (declining catecholamine stores); ~25% remain permanently hypertensive
- Electrolyte correction: monitor for hypokalemia and other abnormalities
- Bilateral adrenalectomy: glucocorticoid and mineralocorticoid replacement essential; single-side resection usually requires only short-term supplementation
4. Special Considerations
Laparoscopic vs. Open Adrenalectomy
Laparoscopic adrenalectomy is standard for most tumors. Tumors >6 cm or with imaging evidence of local invasion may require open resection. Hemodynamic instability can be comparable between approaches; close surgeon-anesthesiologist communication is critical regardless of technique.
Bilateral Pheochromocytoma (MEN2, VHL)
Both glands are removed; immediate steroid replacement is mandatory. These patients carry germline mutations (RET, VHL, SDHx) and require lifelong surveillance.
Pregnancy
Pheochromocytoma in pregnancy carries extreme maternal and fetal risk. α-blockade with phenoxybenzamine is used; β-blockade is added carefully. Surgical resection is preferred in the second trimester; cesarean delivery at term with simultaneous or staged tumor resection is considered in the third trimester.
Summary of Key Principles
| Phase | Key Action |
|---|---|
| Preoperative | α-blockade ≥7–14 days; β-blockade only after α; volume repletion; cardiac evaluation |
| Induction | Arterial line pre-induction; avoid ketamine/histamine-releasing drugs; deep anesthesia before laryngoscopy |
| Maintenance | Short-acting vasoactives ready; MgSO₄ infusion; meticulous hemodynamic communication |
| Post-vein ligation | Aggressive fluids; phenylephrine/norepinephrine; discontinue vasodilators |
| Postoperative | ICU monitoring; glucose every 1–2 h; vasopressors as needed; steroid cover if bilateral |
Sources: Miller's Anesthesia, 10th ed. (p. 4241–4246); Campbell Walsh Wein Urology, 12th ed. (p. 3151–3153); Sabiston Textbook of Surgery, 21st ed. (p. 1576–1577)
This is a shared conversation. Sign in to Orris to start your own chat.